Life Extension Final Clerance Sale

Life Extension Magazine

Life Extension Magazine January 2014
As We See It  

Outwitting Our Aging Brain

By William Faloon

References

  1. Available at: http://stroke.ahajournals.org/content/24/1/94.full.pdf. Accessed October 7, 2013.
  2. Birdsill AC, Carlsson CM, Willette AA, et al. Low cerebral blood flow is associated with lower memory function in metabolic syndrome. Obesity (Silver Spring). 2013 Jul;21(7):1313-20.
  3. Alosco ML, Spitznagel MB, Cohen R, et al. Reduced cerebral perfusion predicts greater depressive symptoms and cognitive dysfunction at a 1-year follow-up in patients with heart failure. Int J Geriatr Psychiatry. 2013 Sep 10.
  4. Bonne O, Krausz Y, Gorfine M, et al. Cerebral hypoperfusion in medication resistant, depressed patients assessed by Tc99m HMPAO SPECT. J Affect Disord. 1996 Dec 16;41(3):163-71.
  5. Grasso MG, Pantano P, Ricci M, et al. Mesial temporal cortex hypoperfusion is associated with depression in subcortical stroke. Stroke. 1994 May;25(5):980-5.
  6. Onoda K, Kuroda Y, Yamamoto Y, et al. Post-stroke apathy and hypoperfusion in basal ganglia: SPECT study. Cerebrovasc Dis. 2011 31(1):6-11.
  7. Farkas E, de Wilde MC, Kiliaan AJ, Luiten PG. Chronic cerebral hypoperfusion-related neuropathologic changes and compromised cognitive status: window of treatment. Drugs Today (Barc). 2002 May;38(5):365-76.
  8. Vicente E, Degerone D, Bohn L, et al. Astroglial and cognitive effects of chronic cerebral hypoperfusion in the rat. Brain Res. 2009 Jan 28;1251:204-12.
  9. Bennett SA, Tenniswood M, Chen JH, et al. Chronic cerebral hypoperfusion elicits neuronal apoptosis and behavioral impairment. Neuroreport. 1998 Jan 5;9(1):161-6.
  10. Hillis AE, Wityk RJ, Barker PB, et al. Subcortical aphasia and neglect in acute stroke: the role of cortical hypoperfusion. Brain. 2002 May;125(Pt 5):1094-104.
  11. Pullicino PM, McClure LA, Wadley VG, et al. Blood pressure and stroke in heart failure in the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Stroke. 2009 Dec;40(12):3706-10.
  12. Román GC. Brain hypoperfusion: a critical factor in vascular dementia. Neurol Res. 2004 Jul;26(5):454-8.
  13. Schuff N, Matsumoto S, Kmiecik J, et al. Cerebral blood flow in ischemic vascular dementia and Alzheimer’s disease, measured by arterial spin-labeling magnetic resonance imaging. Alzheimers Dement. 2009 Nov;5(6):454-62.
  14. de la Torre JC. Critical threshold cerebral hypoperfusion causes Alzheimer’s disease? Acta Neuropathol. 1999 Jul;98(1):1-8.
  15. Kim HA, Miller AA, Drummond GR, et al. Vascular cognitive impairment and Alzheimer’s disease: role of cerebral hypoperfusion and oxidative stress. Naunyn Schmiedebergs Arch Pharmacol. 2012 Oct;385(10):953-9.
  16. Nishimura T, Hashikawa K, Fukuyama H, et al. Decreased cerebral blood flow and prognosis of Alzheimer’s disease: a multicenter HMPAO-SPECT study. Ann Nucl Med. 2007 Jan;21(1):15-23.
  17. Liu Y, Zhu X, Feinberg D, et al. Arterial spin labeling MRI study of age and gender effects on brain perfusion hemodynamics. Magn Reson Med. 2012 Sep;68(3):912-22.
  18. Alosco ML, Brickman AM, Spitznagel MB, et al. Independent and interactive effects of blood pressure and cardiac function on brain volume and white matter hyperintensities in heart failure. J Am Soc Hypertens. 2013 Sep-Oct;7(5):336-43.
  19. Iadecola C, Davisson RL. Hypertension and cerebrovascular dysfunction. Cell Metab. 2008 Jun;7(6):476-84.
  20. Jennings JR, Mendelson DN, Muldoon MF, et al. Regional grey matter shrinks in hypertensive individuals despite successful lowering of blood pressure. J Hum Hypertens. 2012 May;26(5):295-305.
  21. Austin BP, Nair VA, Meier TB, et al. Effects of hypoperfusion in Alzheimer’s disease. J Alzheimers Dis. 2011;26 Suppl 3:123-33.
  22. Chen W, Song X, Beyea S, D’Arcy R, Zhang Y, Rockwood K. Advances in perfusion magnetic resonance imaging in Alzheimer’s disease. Alzheimers Dement . 2011 Mar;7(2):185-96.
  23. Pintó X, Corbella E, Valdivielso, Mostaza J. Prevalence of metabolic syndrome in hypertriglyceridaemic patients: higher than it may appear. Curr Med Res Opin. 2013 Oct 16.
  24. Tsujimura A, Miyagawa Y, Takezawa K, et al. Is low testosterone concentration a risk factor for metabolic syndrome in healthy middle-aged men? Urology. 2013 Oct;82(4):814-9.
  25. Rabijewski M, Papierska L, Kozakowski J, Zgliczynski W. The relationship between androgens concentrations (testosterone and dehydroepiandrosterone sulfate) and metabolic syndrome in non-obese elderly men. Endokrynol Pol. 2007 Nov-Dec;58(6):496-504.
  26. Deedwania PC, Gupta R. Management issues in the metabolic syndrome. J Assoc Physicians India. 2006 Oct;54:797-810.
  27. Available at: http://www.augustatech.edu/anatomy/chapter%2020.htm. Accessed October 22, 2013.
  28. Available at: http://education.mrsec.wisc.edu/36.htm. Accessed October 22, 2013.
  29. Available at: http://faculty.stcc.edu/AandP/AP/AP2pages/Units18to20/vessels/capillar.htm. Accessed October 22, 2013.
  30. Available at: http://www.mdconsult.com/books/page.do?eid=4-u1.0-B978-1-4377-0974-2..00030-0&isbn=978-1-4377-0974-2&type=bookPage&from=content&uniqId=428111871-2. Accessed October 22, 2013.
  31. Rosolowsky M, Weiss HR. Effect of blood coagulation and platelet aggregation on perfusable capillaries and arterioles in ischemic and nonischemic myocardium. Microvasc Res. 1987 Jul;34(1):69-83.
  32. Available at: http://www.columbia.edu/~kj3/Chapter6.html. Accessed October 22, 2013.
  33. Available at: http://www.jappl.org/content/100/1/328.full. Accessed October 22, 2013.
  34. Lin HC, Liu HW, Lin SF. Study on the effect of various conditions and age to blood platelet aggregation test. Gaoxiong Yi Xue Ke Xue Za Zhi. 1990 Dec;6(12):636-42.
  35. Available at: http://www.mdguidelines.com/arterial-embolism-and-thrombosis. Accessed October 22, 2013.
  36. Terwecoren A, Steen E, Benoit D, Boon P, Hemelsoet D. Ischemic stroke and hyperhomocysteinemia: truth or myth? Acta Neurol Belg. 2009 Sep;109(3):181-8.
  37. Tang WB, Li MX, Li GQ, Cai JD, Wei S, Wan YB. Changes of mean platelet volume, fibrinogen content and blood rheology in peripheral blood of youth patients with cerebral infarction. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Apr;20(2):390-3.
  38. Eikelboom JW, Hankey GJ, Baker RI, et al. C-reactive protein in ischemic stroke and its etiologic subtypes. J Stroke Cerebrovasc Dis. 2003 Mar-Apr;12(2):74-81.
  39. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke--secondary publication. Ugeskr Laeger. 2009 Jun 22;171(26):2188-91.
  40. Feng C, Bai X, Xu Y, Hua T, Huang J, Liu XY. Hyperhomocysteinemia associates with small vessel disease more closely than large vessel disease. Int J Med Sci. 2013 10(4):408-12.
  41. Machlus KR, Cardenas JC, Church FC, Wolberg AS. Causal relationship betweenhyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. Blood. 2011 May 5;117(18):4953-63.
  42. Apetrei E, Ciobanu-Jurcut R, Rugina M, Gavrila A, Uscatescu V. C-reactive protein, prothrombotic imbalance and endothelial dysfunction in acute coronary syndromes without ST elevation. Rom J Intern Med. 2004 42(1):95-102.
  43. Available at: http://atvb.ahajournals.org/content/22/2/211.full. Accessed October 23. 2013.
  44. Furuäng L, Wollmer P, Siennicki-Lantz A, Elmståhl S. Cardiac ventricular dimensions predict cognitive decline and cerebral blood flow abnormalities in aging men. BMC Geriatr. 2013 May 15;13:45.
  45. Furuäng L, Siennicki-Lantz A, Elmståhl S. Reduced cerebral perfusion in elderly men with silent myocardial ischaemia and nocturnal blood pressure dipping. Atherosclerosis. 2011 Jan;214(1):231-6.
  46. Matthews RT, Yang L, Browne S, Baik M, Beal MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8892-7.
  47. Hagen TM, Ingersoll RT, Lykkesfeldt J, Liu J, Wehr CM, Vinarsky V, Bartholomew JC, Ames AB. (R)-alpha-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate. FASEB J. 1999 Feb;13(2):411-8.
  48. Pesce V, Fracasso F, Cassano P, Lezza AM, Cantatore P, Gadaleta MN. Acetyl-L-carnitine supplementation to old rats partially reverts the age-related mitochondrial decay of soleus muscle by activating peroxisome proliferator-activated receptor gamma coactivator-1alpha-dependent mitochondrial biogenesis. Rejuvenation Res. 2010 Apr-Jun;13(2-3):148-51.
  49. Gomez LA, Heath SH, Hagen TM. Acetyl-L-carnitine supplementation reverses the age-related decline in carnitine palmitoyltransferase 1 (CPT1) activity in interfibrillar mitochondria without changing the L-carnitine content in the rat heart. Mech Ageing Dev. 2012 Feb-Mar;133(2-3):99-106.
  50. Zhu BQ, Zhou HZ, Teerlink JR, Karliner JS. Pyrroloquinoline quinone (PQQ) decreases myocardial infarct size and improves cardiac function in rat models of ischemia and ischemia/reperfusion. Cardiovasc Drugs Ther. 2004 Nov;18(6):421-31.
  51. Chowanadisai W, Bauerly KA, Tchaparian E, Wong A, Cortopassi GA, Rucker RB. Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1a expression. J Biol Chem. 2010 Jan 1;285(1):142-52.
  52. Tao R, Karliner JS, Simonis U, et al. Pyrroloquinoline quinone preserves mitochondrial function and prevents oxidative injury in adult rat cardiac myocytes. Biochem Biophys Res Commun. 2007 Nov 16;363(2):257-62.
  53. Zhang Y, Feustel PJ, Kimelberg HK. Neuroprotection by pyrroloquinoline quinone (PQQ) in reversible middle cerebral artery occlusion in the adult rat. Brain Res. 2006 Jun 13;1094(1):200-6.
  54. Schuster L, Essig M, Schröder J. Normal aging and imaging correlations. Radiologe. 2011 Apr;51(4):266-72.
  55. Borroni B, Agosti C, Premi E, et al. The FTLD-modified Clinical Dementia Rating scale is a reliable tool for defining disease severity in frontotemporal lobar degeneration: evidence from a brain SPECT study. Eur J Neurol. 2010 May;17(5):703-7.
  56. Li L, Wang Y, Yan J, et al. Chongqing Aging Study Group. Clinical predictors of cognitive decline in patients with mild cognitive impairment: The Chongqing aging study. J Neurol. 2012 Jul;259(7):1303-11.
  57. Cai Y, Xiong K, Zhang XM, et al. β-Secretase-1 elevation in aged monkey and Alzheimer’s disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and β-amyloid accumulation. Eur J Neurosci. 2010 Oct;32(7):1223-38.
  58. Brown WR, Thore CR. Review: cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol Appl Neurobiol. 2011 Feb;37(1):56-74.
  59. Casson IR, Viano DC, Powell JW, Pellman EJ. Twelve years of national football league concussion data. Sports Health. 2010 Nov;2(6):471-83.
  60. Available at: http://www.deseretnews.com/article/383760/CONCUSSIONS-FORCE-MERRIL-HOGE-TO-RETIRE.html?pg=all. Accessed October 22, 2013.
  61. Available at: http://articles.philly.com/1994-01-24/sports/25822971_1_troy-aikman-cowboys-coach-jimmy-johnson-cowboys-trainer-kevin-o-neill. Accessed October 22, 2013.
  62. Available at: http://articles.latimes.com/2000/jun/09/sports/sp-39252. Accessed October 22,2013.
  63. Amen DG, Wu JC, Taylor D, Willeumier K. Reversing brain damage in former NFL players: implications for traumatic brain injury and substance abuse rehabilitation. J Psychoactive Drugs. 2011 Jan-Mar;43(1):1-5.
  64. Bazan NG, Musto AE, Knott EJ. Endogenous signaling by omega-3 docosahexaenoic acid-derived mediators sustains homeostatic synaptic and circuitry integrity. Mol Neurobiol. 2011 Oct;44(2):216-22.
  65. Palacios-Pelaez R, Lukiw WJ, Bazan NG. Omega-3 essential fatty acids modulate initiation and progression of neurodegenerative disease. Mol Neurobiol. 2010 Jun;41(2-3):367-74.
  66. Pu H, Guo Y, Zhang W, et al. Omega-3 polyunsaturated fatty acid supplementation improves neurologic recovery and attenuates white matter injury after experimental traumatic brain injury. J Cereb Blood Flow Metab. 2013 Sep;33(9):1474-84.
  67. Szilágyi G, Nagy Z, Balkay L, et al. Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study. J Neurol Sci. 2005 Mar 15;229-230:275-84.
  68. Hadjiev D. Asymptomatic ischemic cerebrovascular disorders and neuroprotection with vinpocetine. Ideggyogy Sz. 2003 May 20;56(5-6):166-72.
  69. Vishnevskiĭ AA, Korotkevich IG, Zhaparalieva ChO. Membrane and functional effects of vinpocetine and tocopherol in rats with experimental cerebral ischemia. Biomed Khim. 2009 Sep-Oct;55(5):635-42.
  70. Valikovics A. Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions. Ideggyogy Sz. 2007 Jul 30;60(7-8):301-10.
  71. Gaal L, Molnar P. Effect of vinpocetine on noradrenergic neurons in rat locus coeruleus. Eur J Pharmacol. 1990 Oct 23;187(3):537-9.
  72. Santos MS, Duarte AI, Moreira PI, Oliveira CR. Synaptosomal response to oxidative stress: effect of vinpocetine. Free Radic Res. 2000 Jan;32(1):57-66.
  73. Chung HS, Harris A, Kristinsson JK, Ciulla TA, Kagemann C, Ritch R. Ginkgo biloba extract increases ocular blood flow velocity. J Ocul Pharmacol Ther. 1999 Jun;15(3):233-40.
  74. Bridi R, Crossetti FP, Steffen VM, et al. The antioxidant activity of standardized extract of Ginkgo biloba (EGb 761) in rats. Phytother Res 2001 15(5):449-51.
  75. Stoll S, Scheuer K, Pohl O, Müller WE. Ginkgo biloba extract (EGb 761) independently improves changes in passive avoidance learning and brain membrane fluidity in the aging mouse. Pharmacopsychiatry. 1996 Jul;29(4):144-9.
  76. Ihl R. Effects of Ginkgo biloba extract EGb 761(®) in dementia with neuropsychiatric features: review of recently completed randomised, controlled trials. Int J Psychiatry Clin Pract. 2013 Nov;17 Suppl 1:8-14.
  77. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, et al; Ginkgo Evaluation of Memory (GEM) Study Investigators. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008 Nov 19;300(19):2253-62
  78. Ahlemeyer B, Krieglstein J. Neuroprotective effects of Ginkgo biloba extract. Cell Mol Life Sci. 2003 Sep;60(9):1779-92.
  79. Maczurek A, Hager K, Kenklies M, et al. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer’s disease. Adv Drug Deliv Rev. 2008 Oct-Nov;60(13-14):1463-70.
  80. Liu J, Head E, Gharib AM, et al. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha -lipoic acid. Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2356-61.
  81. Pershadsingh HA. Alpha-lipoic acid: physiologic mechanisms and indications for the treatment of metabolic syndrome. Expert Opin Investig Drugs. 2007 Mar;16(3):291-302.
  82. Astiz M, de Alaniz MJ, Marra CA. The oxidative damage and inflammation caused by pesticides are reverted by lipoic acid in rat brain. Neurochem Int. 2012 Dec;61(7):1231-41.
  83. Poon HF, Calabrese V, Calvani M, Butterfield DA. Proteomics analyses of specific protein oxidation and protein expression in aged rat brain and its modulation by L-acetylcarnitine: insights into the mechanisms of action of this proposed therapeutic agent for CNS disorders associated with oxidative stress. Antioxid Redox Signal. 2006 Mar-Apr;8(3-4):381-94.
  84. Long J, Gao F, Tong L, Cotman CW, Ames BN, Liu J. Mitochondrial decay in the brains of old rats: ameliorating effect of alpha-lipoic acid and acetyl-L-carnitine. Neurochem Res. 2009 Apr;34(4):755-63.
  85. Wilson AD, Hart A, Wiberg M, Terenghi G. Acetyl-l-carnitine increases nerve regeneration and target organ reinnervation - a morphological study. J Plast Reconstr Aesthet Surg. 2010 Jul;63(7):1186-95.
  86. Shang YZ, Ye JW, Tang XC. Improving effects of huperzine A on abnormal lipid peroxidation and superoxide dismutase in aged rats. Zhongguo Yao Li Xue Bao. 1999 Sep;20(9):824-8.
  87. Zhang HY, Yan H, Tang XC. Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase. Cell Mol Neurobiol. 2008 Feb;28(2):173-83.
  88. Wang J, Zhang HY, Tang XC. Huperzine a improves chronic inflammation and cognitive decline in rats with cerebral hypoperfusion. J Neurosci Res. 2010 Mar;88(4):807-15.
  89. Hoffer ME, Balaban C, Slade MD, Tsao JW, Hoffer B. Amelioration of acute sequelae of blast induced mild traumatic brain injury by N-acetyl cysteine: a double-blind, placebo controlled study. PLoS One. 2013;8(1):e54163.
  90. Holmay MJ, Terpstra M, Coles LD, et al. N-acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases. Clin Neuropharmacol . 2013 Jul-Aug;36(4):103-6.
  91. Pawlas N, Małecki A. Neuroprotective effect of N-acetylcysteine in neurons exposed to arachidonic acid during simulated ischemia in vitro. Pharmacol Rep. 2009 Jul-Aug;61(4):743-50.
  92. Wang X, Svedin P, Nie C, et al. N-acetylcysteine reduces lipopolysaccharide-sensitized hypoxic-ischemic brain injury. Ann Neurol. 2007 Mar;61(3):263-71.
  93. Khan M, Sekhon B, Jatana M, et al. Administration of N-acetylcysteine after focal cerebral ischemia protects brain and reduces inflammation in a rat model of experimental stroke. J Neurosci Res. 2004 May 15;76(4):519-27.
  94. Kamphuis PJ, Scheltens P. Can nutrients prevent or delay onset of Alzheimer’s disease? J Alzheimers Dis. 2010;20(3):765-75.
  95. Kidd PM. Alzheimer’s disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. Altern Med Rev. 2008 Jun;13(2):85-115.
  96. Ramani A, Jensen JH, Helpern JA. Quantitative MR imaging in Alzheimer disease. Radiology. 2006 Oct;241(1):26-44.
  97. Roher AE, Debbins JP, Malek-Ahmadi M, et al. Cerebral blood flow in Alzheimer’s disease. Vasc Health Risk Manag. 2012 8:599-611.
  98. Johnson NA, Jahng GH, Weiner MW, et al. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology. 2005 Mar;234(3):851-9.
  99. Alexopoulos P, Sorg C, Förschler A, et al. Perfusion abnormalities in mild cognitive impairment and mild dementia in Alzheimer’s disease measured by pulsed arterial spin labeling MRI. Eur Arch Psychiatry Clin Neurosci. 2012 Feb;262(1):69-77.
  100. Maarouf CL, Daugs ID, Kokjohn TA, et al. Alzheimer’s disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging. PLoS One. 2011 6(11):e27291.
  101. Alegret M, Cuberas-Borrós G, Vinyes-Junqué G, et al. A two-year follow-up of cognitive deficits and brain perfusion in mild cognitive impairment and mild Alzheimer’s disease. J Alzheimers Dis. 2012 30(1):109-20.
  102. Available at: http://www.jneurosci.org/content/33/16/6928.short. AccessedOctober 7, 2013.
  103. Bagoly E, Fehér G, Szapáry L. The role of vinpocetine in the treatment of cerebrovascular diseases based in human studies. Orv Hetil. 2007 Jul 22;148(29):1353-8.
  104. Erickson KI, Voss MW, Prakash RS, et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):3017-22.
  105. Davenport MH, Hogan DB, Eskes GA, Longman RS, Poulin MJ. Cerebrovascular reserve: the link between fitness and cognitive function? Exerc Sport Sci Rev. 2012 Jul;40(3):153-8.
  106. Xu Y, Zhang JJ, Xiong L, Zhang L, Sun D, Liu H. Green tea polyphenols inhibit cognitive impairment induced by chronic cerebral hypoperfusion via modulating oxidative stress. J Nutr Biochem. 2010 Aug;21(8):741-8.
  107. Williamson KS, Gabbita SP, Mou S et al. The nitration product 5-nitro-gamma-tocopherol is increased in the Alzheimer brain. Nitric Oxide. 2002 Mar;6(2):221-7.
  108. Hussein G, Sankawa U, Goto H, Matsumoto K, Watanabe H. Astaxanthin, a carotenoid with potential in human health and nutrition. J Nat Prod. 2006 Mar;69(3):443-9.
  109. Mattei R, Polotow TG, Vardaris CV, et al. Astaxanthin limits fish oil-related oxidative insult in the anterior forebrain of Wistar rats: putative anxiolytic effects? Pharmacol Biochem Behav. 2011 Sep;99(3):349-55.
  110. Wu S, Ren J. Benfotiamine alleviates diabetes-induced cerebral oxidative damage independent of advanced glycation end-product, tissue factor and TNF-alpha. Neurosci Lett. 2006 Feb 13;394(2):158-62.
  111. Ohwada K, Takeda H, Yamazaki M, et al. Pyrroloquinoline quinone (PQQ) prevents cognitive deficit caused by oxidative stress in rats. J Clin Biochem Nutr. 2008 Jan;42:29-34.
  112. Lovell MA, Xie C, Xiong S, Markesbery WR. Protection against amyloid beta peptide and iron/hydrogen peroxide toxicity by alpha lipoic acid. J Alzheimers Dis. 2003 Jun;5(3):229-39.
  113. Shirpoor A, Minassian S, Salami S, Khadem-Ansari MH, Yeghiazaryan M. Alpha--lipoic acid decreases DNA damage and oxidative stress induced by alcohol in the developing hippocampus and cerebellum of rat. Cell Physiol Biochem. 2008;22(5-6):769-76.
  114. Hipkiss AR, Preston JE, Himswoth DT, Worthington VC, Abbot NJ. Protective effects of carnosine against malondialdehyde-induced toxicity towards cultured rat brain endothelial cells. Neurosci Lett. 1997 Dec 5;238(3):135-8.
  115. Rajanikant GK, Zemke D, Senut MC, et al. Carnosine is neuroprotective against permanent focal cerebral ischemia in mice. Stroke. 2007 Nov;38(11):3023-31.
  116. Morris MC, Evans DA, Bienias JL, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol. 2003 Jul;60(7):940-6.
  117. Patyar S, Prakash A, Modi M, Medhi B. Role of vinpocetine in cerebrovascular diseases. Pharmacol Rep. 2011 63(3):618-28.
  118. Bönöczk P, Panczel G, Nagy Z. Vinpocetine increases cerebral blood flow and oxygenation in stroke patients: a near infrared spectroscopy and transcranial Doppler study. Eur J Ultrasound. 2002 Jun;15(1-2):85-91.
  119. Solanki P, Prasad D, Muthuraju S, Sharma AK, Singh SB, Ilavzhagan G. Preventive effect of piracetam and vinpocetine on hypoxia-reoxygenation induced injury in primary hippocampal culture. Food Chem Toxicol. 2011 Apr;49(4):917-22.
  120. Kim BW, Koppula S, Kim JW, et al. Modulation of LPS-stimulated neuroinflammation in BV-2 microglia by Gastrodia elata: 4-hydroxybenzyl alcohol is the bioactive candidate. J Ethnopharmacol. 2012 Jan 31;139(2):549-57.
  121. Available at: http://ntp.niehs.nih.gov/ntp/htdocs/Chem_Background/ExSumPdf/Vinpocetine091613_508.pdf. Accessed October 23, 2013.
  122. Kim HJ, Hwang IK, Won MH. Vanillin, 4-hydroxybenzyl aldehyde and 4-hydroxybenzyl alcohol prevent hippocampal CA1 cell death following global ischemia. Brain Res. 2007 Nov 21;1181:130-41.
  123. Zhao X, Zou Y, Xu H, et al. Gastrodin protect primary cultured rat hippocampal neurons against amyloid-beta peptide-induced neurotoxicity via ERK1/2-Nrf2 pathway. Brain Res. 2012 Oct 30;1482:13-21.
  124. Ahn EK, Jeon HJ, Lim EJ, Jung HJ, Park EH. Anti-inflammatory and anti-angiogenic activities of Gastrodia elata Blume. J Ethnopharmacol. 2007 Apr 4;110(3):476-82.
  125. Dai JN, Zong Y, Zhong LM, et al. Gastrodin inhibits expression of inducible NO synthase, cyclooxygenase-2 and proinflammatory cytokines in cultured LPS-stimulated microglia via MAPK pathways. PLoS One. 2011 6(7):e21891.
  126. Du X, Mao R, Liu Y, Li Y, Shan Y. Gastrodine represses expression of IL-1 beta, IL-6 induced by hyperglycemia in gitter cells. Zhongguo Zhong Yao Za Zhi. 2009 Jun;34(12):1535-9.
  127. Hwang SM, Lee YJ, Kang DG, Lee HS. Anti-inflammatory effect of Gastrodia elata rhizome in human umbilical vein endothelial cells. Am J Chin Med. 2009 37(2):395-406.
  128. An SJ, Park SK, Hwang IK, et al. Gastrodin decreases immunoreactivities of gamma-aminobutyric acid shunt enzymes in the hippocampus of seizure-sensitive gerbils. J Neurosci Res. 2003 Feb 15;71(4):534-43.
  129. Bie X, Chen Y, Han J, Dai H, Wan H, Zhao T. Effects of gastrodin on amino acids after cerebral ischemia-reperfusion injury in rat striatum. Asia Pac J Clin Nutr. 2007 16 Suppl 1:305-8.
  130. Fu L, Mao YH, Gao Y, Liu L, Wang ZP, Li LC. Expression of NR1 mRNA of NMDA receptor by gastrodine on hypoxia injury in cultured rat cerebral cortical neurons. Zhongguo Zhong Yao Za Zhi. 2008 May;33(9):1049-52.
  131. Ha JH, Lee DU, Lee JT, et al. 4-Hydroxybenzaldehyde from Gastrodia elata B1. is active in the antioxidation and GABAergic neuromodulation of the rat brain. J Ethnopharmacol. 2000 Nov;73(1-2):329-33.
  132. Ha JH, Shin SM, Lee SK, et al. In vitro effects of hydroxybenzaldehydes from Gastrodia elata and their analogues on GABAergic neurotransmission, and a structure-activity correlation. Planta Med. 2001 Dec;67(9):877-80.
  133. Jung JW, Yoon BH, Oh HR, et al. Anxiolytic-like effects of Gastrodia elata and its phenolic constituents in mice. Biol Pharm Bull. 2006 Feb;29(2):261-5.
  134. Shin EJ, Bach JH, Nguyen TT, et al. Gastrodia elata Bl attenuates cocaine-induced conditioned place preference and convulsion, but not behavioral sensitization in mice: Importance of GABA(A) receptors. Curr Neuropharmacol. 2011 Mar;9(1):26-9.
  135. Shuchang H, Qiao N, Piye N, Mingwei H, Xiaoshu S, Feng S, Sheng W, Opler M. Protective effects of gastrodia elata on aluminium-chloride-induced learning impairments and alterations of amino acid neurotransmitter release in adult rats. Restor Neurol Neurosci. 2008 26(6):467-73.
  136. Xu X, Lu Y, Bie X. Protective effects of gastrodin on hypoxia-induced toxicity in primary cultures of rat cortical neurons. Planta Med. 2007 Jun;73(7):650-4.
  137. Zeng X, Zhang Y, Zhang S, Zheng X. A microdialysis study of effects of gastrodin on neurochemical changes in the ischemic/reperfused rat cerebral hippocampus. Biol Pharm Bull. 2007 Apr;30(4):801-4.
  138. Descamps E, Petrault-Laprais M, Maurois P, et al. Experimental stroke protection induced by 4-hydroxybenzyl alcohol is cancelled by bacitracin. Neurosci Res. 2009 Jun;64(2):137-42.
  139. Kam KY, Yu SJ, Jeong N, et al. p-Hydroxybenzyl alcohol prevents brain injury and behavioral impairment by activating Nrf2, PDI, and neurotrophic factor genes in a rat model of brain ischemia. Mol Cells. 2011 Mar;31(3):209-15.
  140. Yu SS, Zhao J, Zheng WP, Zhao Y. Neuroprotective effect of 4-hydroxybenzyl alcohol against transient focal cerebral ischemia via anti-apoptosis in rats. Brain Res. 2010 Jan 13;1308:167-75.
  141. Zeng X, Zhang S, Zhang L, Zhang K, Zheng X. A study of the neuroprotective effect of the phenolic glucoside gastrodin during cerebral ischemia in vivo and in vitro. Planta Med. 2006 Dec;72(15):1359-65.
  142. Zhang CY, Du GY, Wang W, et al. Effects of tianma gouteng fang on transmitter amino acids in the hippocampus extracellular liquids in freely moving rats subjected to brain ischemia. Zhongguo Zhong Yao Za Zhi. 2004 Nov;29(11):1061-5.
  143. An H, Kim IS, Koppula S, et al. Protective effects of Gastrodia elata Blume on MPP+-induced cytotoxicity in human dopaminergic SH-SY5Y cells. J Ethnopharmacol. 2010 Jul 20;130(2):290-8.
  144. Kim IS, Choi DK, Jung HJ. Neuroprotective effects of vanillyl alcohol in Gastrodia elata Blume through suppression of oxidative stress and anti-apoptotic activity in toxin-induced dopaminergic MN9D cells. Molecules. 2011 16(7):5349-61.
  145. Liu ZH, Hu HT, Feng GF, Zhao ZY, Mao NY. Protective effects of gastrodin on the cellular model of Alzheimer’s disease induced by Abeta25-35. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 Jul;36(4):537-40.
  146. Mishra M, Huang J, Lee YY, et al. Gastrodia elata modulates amyloid precursor protein cleavage and cognitive functions in mice. Biosci Trends. 2011 5(3):129-38.
  147. Ramachandran U, Manavalan A, Sundaramurthi H, et al. Tianma modulates proteins with various neuro-regenerative modalities in differentiated human neuronal SH-SY5Y cells. Neurochem Int. 2012 Jun;60(8):827-36.
  148. Epstein AJ, Polsky D, Yang F, Yang L, Groeneveld PW. Coronary revascularization trends in the United States, 2001-2008. JAMA. 2011 May 4;305(17):1769-76.
  149. Available at: http://digitalcommons.liberty.edu/cgi/viewcontent.cgi?article=1259&context=honors. Accessed October 7, 2013.
  150. Newman MF, Kirchner JL, Phillips-Bute B, et al. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. N Engl J Med. 2001 Feb 8;344(6):395-402.
  151. Zhang Z, Ma P, Xu Y, Zhan M, Zhang Y, Yao S, Zhang S. Preventive effect of gastrodin on cognitive decline after cardiac surgery with cardiopulmonary bypass: a double-blind, randomized controlled study. J Huazhong Univ Sci Technolog Med Sci. 2011 Feb;31(1):120-7.
  152. Available at: http://stroke.ahajournals.org/content/42/8/2351.full.pdf. Accessed October 7, 2013.
  153. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013 May 7;80(19):1778-83.
  154. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke. 1997 Mar;28(3):652-9.
  155. O’Sullivan M. Leukoaraiosis. Pract Neurol. 2008 Feb;8(1):26-38.